Sabril advisory committee postponed
FDA postpones two-day advisory committee meeting on Ovation's Sabril "due to difficulties in empanelling the necessary experts due to both scheduling conflicts and conflict-of-interest." The Peripheral and Central Nervous System Drugs Advisory Committee was scheduled to meet Aug. 6-7 to review vigabatrin as adjunctive therapy for the treatment of refractory complex partial seizures in adults and treatment of infantile spasms (1"The Pink Sheet," July 14, 2008, In Brief). Ovation expects to receive an "approvable" letter in late August, followed by a final decision by the end of the fourth quarter
You may also be interested in...
Ovation's Sabril (vigabatrin) is going before FDA's Peripheral and Central Nervous System Drugs Advisory Committee for two epilepsy indications. GABA-transaminase inhibitor, which has a long 34-year history, will be reviewed Aug. 6-7 in Silver Spring, Md. Ovation is seeking approval for two indications, as adjunctive therapy for the treatment of refractory complex partial seizures in adults and treatment of infantile spasms. The firm said FDA had accepted the two NDAs for Sabril and granted priority review for the infantile indication in February. Ovation says now that it expects final approval by the end of the fourth quarter. The delay is nominal given that vigabatrin was originally deemed "approvable" by FDA in 1997 for adult seizures; the product was then owned by Aventis (now Sanofi-Aventis). One safety issue likely to be raised by the panel is a peripheral visual field defect
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.